18 (twice amended). The method of claim 12 [16] wherein the bifunctional binding agent further comprises a moiety selected from one or more of the following: biotin [mimetics], homophyllic peptides, and human Fc fragments.

19. (amended) The method of claim 12 [16] wherein the targeting component binds to a ligand/receptor complex.

21 (twice amended). The method of claim 20 wherein the growth factor/growth factor receptor is a VEGF/VEGF receptor[, or a peptide mimetic of VEGF, or a VEGF-like molecule bound to the VEGF receptor].

REMARKS

This supplemental response is in response to the office action mailed 4 May 2001 and to the telephone interview with the Examiner on 1 November 2001. Entry of the above is respectfully requested.

Following the entry of this amendment claims 12 – 14 and 17–25 are pending. In view of the amendments set out above and the following remarks, reconsideration is respectfully requested. Applicants attach a clean copy of the claims that reflect the amendments to the claims made in the response filed 23 July and in this supplemental amendment.

During the telephone interview, the Examiner acknowledged that the submissions in Applicants response of 23 July 2001 overcame the rejections/objections in Paragraphs 2, 3, 4, 6, 8, and 13. Applicants appreciate this acknowledgment and assistance in expediting the continued prosecution of this application.

Concerning paragraphs 10 and 11, in the telephone interview, the Examiner indicated that she had not yet reached a conclusion regarding the sufficiency of Applicants' arguments in the previous response. Solely for the purpose of expediting the prosecution of this application, Applicants offered to delete "mimetic", "VEGF-like", and "functional equivalents" from claims 17, 18, and 21. Applicants emphasize that this action is solely for the purpose of quickly expediting